| | | 急性白血病外周血T细胞CD28和CD137的表达
| | 毕业论文下载 作者：马肖容 张王刚 杨惠云 田玮
【关键词】 ,CD28
Expression of CD28 and CD137 in peripheral blood T cells in acute leukemia
【Abstract】 AIM: To study the expression characteristics of costimulatory molecules CD28 and CD137 (41BB) in peripheral blood T cells in human leukemia before and after the chemotherapy and to explore their significance in antileukemia immunity. METHODS: The expression of costimulatory molecules CD28 and CD137 in T cells was measured in 38 patients with acute leukemia (AL) before and after chemotherapy by immunofluorescence and FACS. The peripheral blood T lymphocyte subsets were also analyzed. RESULTS: ① The level of CD28, CD3, CD4 and CD4/CD8 in AL patients before chemotherapy was lower but CD137 was higher than those in control markedly (P<0.05). ② The level of CD28, CD3, CD4 and CD4/CD8 increased in complete remission (CR) and partial remission (PR) patients after chemotherapy but CD137 decreased distinctly compared with that before chemotherapy (P<0.05). The level in CR patients was close to that in the control. No significant change was found in nonremission (NR) patients (P>0.05). CONCLUSION: CD28 and CD137 are important costimulatory molecules during the pathogenesis of AL and antileukemia immunity. Their abnormal level may partly be responsible for AL and be closely related with the clinical curative effects. It may be an important means to treat human leukemia immunogenetically by regulating the expression of CD28 and CD137 in T cells and by correcting the immunodeficiency of AL patients.
【Keywords】 CD28; CD137; T lymphocyte; acute leukemia
【摘要】 目的毕业论文下载：研究共刺激分子CD28和CD137（41BB）在人急性白血病（AL）治疗前后外周血T细胞上的毕业论文下载表达特点，探讨其与临床疗效的关系. 方法：应用免疫荧光标记及流式细胞术（FACS）检测了38例AL患者治疗前后外周血T细胞表面共刺激分子CD28和CD137的表达，并分析了T淋巴细胞亚群变化情况. 结果：①治疗前AL患者CD28, CD3, CD4, CD4/CD8较对照组显著降低，而CD137显著增高（P<0.05）；②治疗后完全缓解（CR）和部分缓解（PR）患者CD28, CD3, CD4, CD4/CD8均较其治疗前显著增高，而CD137显著降低（P<0.05），CR患者接近对照者，而未缓解（NR）患者以上指标无显著变化（P>0.05）. 结论：CD28和CD137是参与急性白血病发病和抗白血病免疫反应的重要共刺激分子，其表达异常可能是急性白血病发病机制之一且与临床疗效密切相关；调节T细胞上CD28和CD137的表达，纠正白血病患者细胞免疫功能缺陷，可能是免疫基因治疗人类急性白血病的重要手段之一，具有一定的临床应用价值.
【关键词】 CD28；CD137；T淋巴细胞；急性白血病
0引言
CD28和CD137（41BB）是迄今发现的T细胞上两种最重要的共刺激分子，它们分别与抗原递呈细胞（APC）上的B71（CD80）和CD137L结合，协同MHCAg信号，提高肿瘤细胞免疫原性，后者包括促进T细胞增殖，分泌细胞因子及增强细胞毒活性（CTL）［1-4］. 这种共刺激分子介导的协同刺激通路虽然是非特异性的，但在抗肿瘤免疫反应中不可缺少［5-7］. 目前对CD137的研究多为小鼠，鲜见人类血液肿瘤共刺激分子的研究报道. 我们检测了急性白血病（AL）患者常规化疗前后外周血T细胞表面CD28和CD137的表达，并分析了T淋巴细胞亚群变化情况，旨在探讨其与临床疗效的关系.
|
| | |
| | | | <<<<<全文未完>>>>> 全文字数约$$$zishu$$$字 | |
| | |
| |
|
教育论文中心